[Treatment of dystrophy, dysplasia and initial stages of vulvar carcinoma in virus infections].
Overall sixty-seven patients with distrophy, dysplasia and valvular carcinoma presenting with human papilloma virus- and herpes simplex-2 virus infections underwent a complex treatment intended for background, precancerous affections of the vulva and for valvular carcinoma, involving the use of antiviral drug preparations laferon, zovirax, lovir (both on the systemic and local basis), and an immunomodulator (decaris). Efficacy of the above treatment option has been shown to be 98.5%.
Tkachuk
T Ie
TIe
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy / Q000821:virology; D018258:Herpesvirus 2, Human; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008875:Middle Aged; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000188:drug therapy / Q000821:virology; D011230:Precancerous Conditions / Q000188:drug therapy*; D014412:Tumor Virus Infections / Q000188:drug therapy / Q000821:virology; D014844:Vulva / Q000473:pathology; D014845:Vulvar Diseases / Q000188:drug therapy / Q000821:virology; D014846:Vulvar Neoplasms / Q000188:drug therapy* / Q000821:virology
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007978:Levamisole
Likuvannia dystrofiï, dysplaziï ta pochatkovykh form raku vul'vy pry virusnomu infikuvanni.